Ultra Compact Inline E-Plane Waveguide Bandpass Filters Using Cross Coupling

This paper presents novel ultra-compact waveguide bandpass filters that exhibit pseudo elliptic responses with ability to place transmission zeros on both sides of the passband to form sharp roll offs. The filters contain E plane extracted pole sections cascaded with cross-coupled filtering blocks. Compactness is achieved by the use of evanescent mode sections and closer arranged resonators modified to shrink in size. The filters containing non-resonating nodes are designed by means of the generalized coupling coefficients (GCC) extraction procedure for the cross-coupled filtering blocks and extracted pole sections. We illustrate the performance of the proposed structures through the design examples of a third and a fourth order filters with center frequencies of 9.2 GHz and 10 GHz respectively. The sizes of the proposed structures suitable for fabricating using the low cost E plane waveguide technology are 38% smaller than ones of the E plane extracted pole filter of the same order.

Clinical potential of oligonucleotide-based therapeutics in the respiratory system

The discovery of an ever-expanding plethora of coding and non-coding RNAs with nodal and causal roles in the regulation of lung physiology and disease is reinvigorating interest in the clinical utility of the oligonucleotide therapeutic class. This is strongly supported through recent advances in nucleic acids chemistry, synthetic oligonucleotide delivery and viral gene therapy that have succeeded in bringing to market at least three nucleic acid-based drugs. As a consequence, multiple new candidates such as RNA interference modulators, antisense, and splice switching compounds are now progressing through clinical evaluation. Here, manipulation of RNA for the treatment of lung disease is explored, with emphasis on robust pharmacological evidence aligned to the five pillars of drug development: exposure to the appropriate tissue, binding to the desired molecular target, evidence of the expected mode of action, activity in the relevant patient population and commercially viable value proposition.